Floatz logo

Imiquimod

Lentigo Maligna

Melanoma and Skin Cancer Trials LimitedSmall moleculePhase 4 / ApprovedDormant
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Lentigo Maligna cohort.

Asset / SponsorPhaseRating
5-ala
Joint Authority for Päijät-Häme Social and Health Care
Phase 4B
INGENOL MEBUTATE
Centre Hospitalier Universitaire de Nice
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2B
Dinaciclib
National Cancer Institute (NCI)
Phase 2CCC
rg4733
National Cancer Institute (NCI)
Phase 2CC
Tazarotene
University of Utah
N/AD

Same molecule, other indications

Imiquimod is also rated in:

human papilloma virus infectionDormant
B
Indicative ·
63 / 100
View asset →
squamous cell intraepithelial neoplasiaDormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →